DA
IBRX icon

Dillon & Associates’s ImmunityBio IBRX Stock Holding History

Dillon & Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$190K Sell
23,800
-2,000
-8% -$13.7K 0.03% 75
2025
Q4 		$52K Hold
25,800
– – 0.01% 77
2025
Q3 		$52K Hold
25,800
– – 0.01% 76
2025
Q2 		$77K Buy
+25,800
New +$69.4K 0.01% 77

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Dillon & Associates's IBRX Position: Q1 2026 in Review

Dillon & Associates reduced its ImmunityBio (IBRX) stake by 7.8% in Q1 2026, selling an estimated $13.7K and leaving 23,800 shares worth $190K. The position accounts for 0.03% of the portfolio, ranked #75.

Dillon & Associates first reported a position in IBRX in Q2 2025 and has held it in 4 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Dillon & Associates held 23,800 shares of ImmunityBio worth $190K as of Q1 2026.
  • Dillon & Associates sold 2,000 ImmunityBio shares in Q1 2026, an estimated $13.7K.
  • ImmunityBio made up 0.03% of Dillon & Associates's portfolio in Q1 2026, its #75 holding.
  • Dillon & Associates first reported a position in ImmunityBio in Q2 2025 and has held it in 4 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Dillon & Associates's 13F filing for Q1 2026, filed 7 May 2026.